Form 4: Marimed Chief Commercial Officer Ryan Crandall Reports RSU Vesting and Tax-Related Share Disposition
Insider Transaction Report
Marimed Inc.'s Chief Commercial Officer, Ryan Crandall, reported the vesting of 62,902 Restricted Stock Units and a subsequent disposition of shares to cover tax obligations on June 15, 2025.
Summary
- Ryan Crandall, Chief Commercial Officer of Marimed Inc. (MRMD), filed a Form 4 reporting transactions that occurred on June 15, 2025.
- A total of 62,902 Restricted Stock Units (RSUs) vested and converted into shares of common stock on a one-for-one basis.
- Concurrently, 21,796 shares of common stock were disposed of by the Issuer to satisfy tax withholding obligations related to the RSU vesting, at a price of $0.0725 per share.
- Following these reported transactions, Mr. Crandall beneficially owns 674,397 shares of Marimed Inc. common stock.
- Additionally, Mr. Crandall holds 125,803 unvested Restricted Stock Units.
Sentiment
Score: 5
Explanation: The filing is a routine Form 4 reporting executive compensation vesting and tax-related share disposition, which is a neutral event for the company's operational or financial performance.
Positives
- The vesting of Restricted Stock Units indicates the fulfillment of executive compensation agreements, aligning management's interests with shareholder value through equity ownership.
Negatives
- The disposition of 21,796 shares was solely for tax withholding purposes, which is a standard practice upon RSU vesting and does not reflect a discretionary sale by the executive.
Future Outlook
The remaining 125,803 Restricted Stock Units held by Mr. Crandall are scheduled to vest in two equal installments on September 15, 2025, and December 15, 2025, in accordance with the terms of his award agreement.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, specifically related to executive compensation. Such filings are common across all publicly traded companies and provide transparency into how executives acquire and dispose of company stock, typically as part of their compensation plans. It does not provide specific insights into broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: Provides transparency regarding executive equity holdings and the mechanics of executive compensation, confirming that a key officer continues to hold a significant equity stake.
- Employees: No direct impact on the broader employee base, but it reflects standard executive compensation practices within the company.
Next Steps
- Remaining Restricted Stock Units held by Ryan Crandall are scheduled to vest in two equal installments on September 15, 2025, and December 15, 2025.
Key Dates
| Date | Description |
|---|---|
| 05/09/2025 | Date when the reported Restricted Stock Units (RSUs) were granted. |
| 06/15/2025 | Date of the reported transactions, including RSU vesting and share disposition. |
| 06/16/2025 | Date the Form 4 filing was signed. |
| 09/15/2025 | First future date for vesting of remaining Restricted Stock Units. |
| 12/15/2025 | Second future date for vesting of remaining Restricted Stock Units. |
Keywords
MARIMED INC., MRMD, Ryan Crandall, Chief Commercial Officer, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Share Disposition, Tax Withholding, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.